Myasthenia Gravis

Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.

It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.


Clinical trials ongoing at the Institute:

  • UCB MG0003 : A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis
  • UCB MG0004 : A randomized, open-label extension study to investigate the long-term safety, tolerability of rozanolixizumab in adult patients with generalized myasthenia gravis
  • UCB MG0007 : A Phase 3, open-label extension (OLE) study to evaluate 6-week treatment cycles of rozanolixizumab in study participants with gMG
  • R3918-MG-2018 : Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
  • MOM-M281-011 : Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis



UCB MG0003

UCB MG0004

UCB MG0007

Intervention rozanolixizumab rozanolixizumab rozanolixizumab
Principal investigator
Sophie Demeret Sophie Demeret Sophie Démette
Study status Ongoing Ongoing Ongoing
Recruitment status Ongoing Stopped Completed
Population Adult Adult Adul
   + infos sur clinical + infos sur clinical






Intervention pozelimab et cemdisiran nipocalimab
Principal investigator Sophie Demeret Sophie Demeret
Sponsor Regeneron Jannsen-Cilag
Study status In preparation Ongoing
Recruitment status In preparation In preparation
Population Adult Adult


Contact :